Has Shelley Ghafoori, MD received payments from drug or device companies?

Yes. Drug and device makers reported $73,033 in general payments to Shelley Ghafoori, MD across 90 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shelley Ghafoori, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shelley Ghafoori, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shelley Ghafoori, MD

Ophthalmology · Austin, TXNPI 1588788830

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $50,530 of the $73,033 with a category attached, or 69.2%. Baxter Healthcare accounts for 63.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $25,194 and has fallen 97.6% since, to $616 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$73,033in general payments, 2019–2025

Across 90 payments — averaging $811.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Baxter Healthcare$46K
Novartis$20K
US Retina LLC$3K
Welch Allyn$1K
AbbVie$500
Biotissue Holdings Inc.$381
plus $2K from 11 others

$2,808,839in research payments, 2019–2025

Across 23 payments — averaging $122,123 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$2.8M

What the payments were for

Consulting fees$50,53069%
Speaking & faculty fees$14,77520%
Grants$5001%
Travel & lodging$1,7462%
Food & beverage$2,6754%
Gifts$1760%
Ownership interest$2,6324%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Baxter Healthcare	24	$46,035
Novartis	27	$20,495
US Retina LLC	5	$2,632
Welch Allyn	1	$1,420
AbbVie	1	$500
Biotissue Holdings Inc.	3	$381
Genentech USA, Inc.	9	$317
Regeneron	2	$300
Genentech, Inc.	3	$287
Carl Zeiss Meditec, Inc.	1	$176
Regeneron Healthcare Solutions, Inc.	3	$156
Optovue, Inc.	1	$100
Astellas Pharma US Inc	3	$80
Apellis Pharmaceuticals, Inc.	3	$73
Alimera Sciences, Inc.	2	$36
Neurotech Pharmaceuticals, Inc.	1	$30
Mallinckrodt Hospital Products Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,033 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas →

Medicare billing

Part B allowed, 2024

$3,654,003

Medicare patients

1,005

Services billed

20,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	130	$4,534
Bromfenac Sodium	30	$2,569
Ketorolac Tromethamine	29	$1,119
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol	13	$1,072
Latanoprost	14	$125
Timolol Maleate	12	$122
Prednisone	12	$22

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Austin

Chirag JhaveriAustin$240K
Sheila BarbarinoAustin$232K
Aaron RollerAustin$202K
Philip StoreyAustin$161K
Robert WongAustin$113K
Farhan IrshadAustin$111K
Edward WoodAustin$110K
Ryan YoungAustin$105K
Steven DellAustin$94K
Michael SingerSan Antonio$1.8M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →